<DOC>
	<DOCNO>NCT02617017</DOCNO>
	<brief_summary>Parkinson 's disease ( PD ) one common neurodegenerative disease , high prevalence elderly . Levodopa induce dyskinesia ( LID ) major motor complication impair quality life patient PD . The mechanism dyskinesia remain unclear , several hypothesis put forward : non continuous , pulsatile stimulation dopaminergic receptor , alteration neurotransmitter within motor striatum glutamate serotonin . Few strategy available treat severe LID : - Medications : reduction dopaminergic treatment , addition amantadine , - Functional neurosurgery . The purpose study investigate efficacy buspirone PD patient suffer dyskinesia . The role serotonin occurrence LID recently demonstrate transplant PD patient test double-blind , single dose achieve . Following administration 10 mg oral buspirone , 5HT1A agonist , LID clearly improve . A antidyskinetic effect buspirone already report 1991 1994 , identification buspirone serotonin receptor agonist report recently . This trial aim ( 1 ) validate serotoninergic hypothesis hyperkinetic levodopa induce dyskinesia ( LID ) Pakinson 's disease patient , ( 2 ) evaluate , phase 3 trial , motor efficacy buspirone improve LID v placebo , ( 3 ) look possible dose/effect relationship ( 4 ) check hypothesis well therapeutic ratio use association buspirone amantadine instead single drug .</brief_summary>
	<brief_title>Buspirone Treatment Iatrogenic Dyskinesias Advanced Parkinson ' Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Buspirone</mesh_term>
	<criteria>Inclusion Criteria The subject outpatient 35 year 80 year age Diagnosis idiopathic Parkinson 's disease accord UK Parkinson 's Disease Society Brain Bank Clinical Diagnosis Criteria Dyskinesias present 25 % wake day accord item 41 MDSUPDRS Dyskinesias least moderately disable item 42 MDSUPDRS The subject able identify dyskinesia , ON OFF , apply his/her state Stable dose antiParkinsonian drug least 4 week screen The subject consider optimally treated time inclusion Written sign inform consent participate study Maximal Hoehn Yahr staging : III `` ON '' phase , IV `` OFF '' Active affiliation social security Menopausal contraception woman Exclusion Criteria Female subject : pregnant lactate Atypical parkinsonian syndrome Weight le 40 Kgs MiniMental State Examination ( MMSE ) less 24 The subject participate another clinical study within past 12 week Planned participation another therapeutic clinical study Previous treatment buspirone , less 6 month Week 0 Known allergy buspirone Known lactose intolerance Clinically significant illness might interfere study Dementia psychiatric illness Drug alcohol abuse Legal incapacity limit legal capacity Deep brain stimulation perform less 12 month protocol initiation , unstable parameter stimulation 4 week week 0 Severe renal / hepatic impairment History seizures epilepsy</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Parkinson disease</keyword>
	<keyword>Levodopa induce dyskinesia</keyword>
</DOC>